These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33813119)

  • 21. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
    Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
    Svensson EM; Svensson RJ; Te Brake LHM; Boeree MJ; Heinrich N; Konsten S; Churchyard G; Dawson R; Diacon AH; Kibiki GS; Minja LT; Ntingiya NE; Sanne I; Gillespie SH; Hoelscher M; Phillips PPJ; Simonsson USH; Aarnoutse R
    Clin Infect Dis; 2018 Jun; 67(1):34-41. PubMed ID: 29917079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].
    Tan S; Ding X; Tan Y; Cai X; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.
    Seijger C; Hoefsloot W; Bergsma-de Guchteneire I; Te Brake L; van Ingen J; Kuipers S; van Crevel R; Aarnoutse R; Boeree M; Magis-Escurra C
    PLoS One; 2019; 14(3):e0213718. PubMed ID: 30870476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review.
    Steingart KR; Jotblad S; Robsky K; Deck D; Hopewell PC; Huang D; Nahid P
    Int J Tuberc Lung Dis; 2011 Mar; 15(3):305-16. PubMed ID: 21333096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a meta-analysis of randomized controlled trials.
    Zhang J; Chen C; Yang J
    Chin Med J (Engl); 2019 Dec; 132(24):2950-2959. PubMed ID: 31833904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
    Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
    Ngo HX; Xu AY; Velásquez GE; Zhang N; Chang VK; Kurbatova EV; Whitworth WC; Sizemore E; Bryant K; Carr W; Weiner M; Dooley KE; Engle M; Dorman SE; Nahid P; Swindells S; Chaisson RE; Nsubuga P; Lourens M; Dawson R; Savic RM
    Clin Infect Dis; 2024 Jun; 78(6):1680-1689. PubMed ID: 38462673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
    Benator D; Bhattacharya M; Bozeman L; Burman W; Cantazaro A; Chaisson R; Gordin F; Horsburgh CR; Horton J; Khan A; Lahart C; Metchock B; Pachucki C; Stanton L; Vernon A; Villarino ME; Wang YC; Weiner M; Weis S;
    Lancet; 2002 Aug; 360(9332):528-34. PubMed ID: 12241657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The relation between bacilli negative conversion rate and the number of combined sensitive antituberculous drugs in intermittent administration of rifampicin for severe pulmonary tuberculosis].
    Tamura M; Yamazaki A; Tamura T; Takano S; Yamazaki M
    Kekkaku; 1973 Jul; 48(7):297-302. PubMed ID: 4200058
    [No Abstract]   [Full Text] [Related]  

  • 33. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
    Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy of pulmonary tuberculosis. Sputum culture conversion in 8 weeks in 84% of patients].
    Nowak D; Radenbach D; Magnussen H
    Dtsch Med Wochenschr; 1987 Sep; 112(36):1367-70. PubMed ID: 3622281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
    Zhang SY; Fu JY; Guo XY; Wu DZ; Zhang T; Li C; Qiu L; Shao CR; Xiao HP; Chu NH; Deng QY; Zhang X; Yan XF; Wang ZL; Zhang ZJ; Jiang X; Zheng YJ; Zheng PY; Zhang HY; Lu ZH
    Infect Dis Poverty; 2020 May; 9(1):50. PubMed ID: 32381098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1975 Jan; 1(7899):119-24. PubMed ID: 46047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifapentine.
    Jarvis B; Lamb HM
    Drugs; 1998 Oct; 56(4):607-16; discussion 617. PubMed ID: 9806107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group.
    Gonzalez-Montaner LJ; Natal S; Yongchaiyud P; Olliaro P
    Tuber Lung Dis; 1994 Oct; 75(5):341-7. PubMed ID: 7841427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
    Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.